Softwr

Healthcare · head to head

Lunit vs Phreesia

Lunit logo

Lunit

Healthcare

FDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography

From
On request
Rated
-
Full reviewWebsite
Phreesia logo

Phreesia

Healthcare

Patient intake, registration and payments platform for medical practices

From
Free
Rated
-
Full reviewWebsite

The short version

  • Only Phreesia has a free tier, so it costs nothing to try first.
  • Each has a real cost: Lunit the regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.; Phreesia no price is published: the vendor states pricing is customised to organisation size, workflows and products used, and is given only as a tailored quote
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Lunit and Phreesia actually diverge.

Attributes where Lunit and Phreesia differ
AttributeLunitPhreesia
Starting priceOn requestFree
Pricing modelquotesubscription
Free tierNoYes

Identical on both: platforms (Web), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Lunit

  • Lunit INSIGHT MMG
  • Lunit INSIGHT DBT
  • Lunit INSIGHT CXR
  • Volpara density assessment
  • Volpara RiskPathways
  • Volpara dose tracking
  • PACS and mammography workstation integration

Only in Phreesia

Nothing recorded that Lunit does not also cover.

What people use each for

The jobs each tool is most often brought in to do.

Lunit

  • A national breast screening programme evaluating AI as a second reader to reduce double reading workload where two human readers are currently mandatednot Phreesia
  • A breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on DBT specificallynot Phreesia
  • An American breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what Volpara is bought fornot Phreesia
  • A tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise filmsnot Phreesia

Phreesia

  • Digital patient intake and registration ahead of an appointmentnot Lunit
  • Collecting patient payments as part of the intake workflownot Lunit
  • Automating clinical screening questionnaires at check-innot Lunit

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Lunit

  • The regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • Detection AI changes recall rates in screening, and the downstream cost of additional diagnostic workup lands on the programme rather than on the software budget, which is the cost most screening business cases omit.
  • Performance is sensitive to the mammography vendor and acquisition protocol, so published results from a Hologic estate do not transfer to a GE or Siemens estate without local validation the buyer must fund.
  • MMG, DBT and CXR are licensed separately and Volpara modules are separate again, so a breast centre wanting detection, density and risk pathways is assembling four line items rather than buying one product.
  • Using AI as a replacement for one of two human readers is a workforce and liability decision that regulators and professional bodies treat differently in each country, so the saving that justifies the purchase may not be permitted where you operate.

Phreesia

  • No price is published: the vendor states pricing is customised to organisation size, workflows and products used, and is given only as a tailored quote
  • The current free access to the Intake platform is time limited and ends on 31 December 2026, with the rate that follows undisclosed
  • A buyer must book a demo before receiving any figure

Pricing, plan by plan

Lunit

On request
  • Lunit INSIGHT$undefined/year
    • Priced per study or per annual examination volume by product
    • MMG, DBT and CXR licensed separately
    • Volpara density and RiskPathways modules quoted separately

Phreesia

Free

No published plan breakdown. See the Phreesia review.

Which should you pick?

Choose Lunit if

  • You need lunit insight mmg.
  • You also want lunit insight dbt.
Lunit review

Choose Phreesia if

  • You want to start without paying.
Phreesia review

Questions people ask

Is Lunit or Phreesia better?
Neither clearly leads. Lunit starts at On request and Phreesia at Free, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Lunit or Phreesia?
Phreesia has a free tier; the other does not. Paid plans start at On request for Lunit and Free for Phreesia.
Does Lunit or Phreesia run on more platforms?
Both run on Web, so platform support will not decide this one for you.
Can I use Phreesia for free?
Yes. Phreesia has a free tier, so you can try it without paying. Lunit starts at On request.
What is Lunit best used for?
Lunit is most often used for a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated, a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically, an american breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what volpara is bought for, a tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise films. Of those, a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated and a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically are not what Phreesia is typically brought in for.
What can Lunit do that Phreesia cannot?
Lunit covers Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT CXR, Volpara density assessment.

Answered from the vendors’ own pages

Lunit: Is Lunit FDA cleared?

Yes for specific products. INSIGHT MMG, INSIGHT DBT and INSIGHT CXR Triage hold FDA 510(k) clearances. INSIGHT Risk, the five year risk prediction model, has been filed but was not cleared at the time of writing.

Phreesia: Is there a free version of Phreesia?

Phreesia offers free access to the complete Phreesia Intake platform through December 31, 2026. Standard subscription pricing begins January 1, 2027, with transparent pricing and no per-message charges or hidden fees.

Source
Lunit: Can Lunit replace a second human reader in screening?

That depends entirely on your jurisdiction and professional body guidance, not on the software. The CE mark permits clinical use; it does not authorise a workforce model.

Phreesia: How is Phreesia priced?

Phreesia pricing is customized based on organization size, workflows, and products used. The company offers transparent subscription pricing with no per-message charges. Specific pricing requires contacting the company via their demo request form for a tailored quote.

Source
Lunit: What did the Volpara acquisition add?

Volumetric breast density measurement, dose tracking and RiskPathways high risk programme management, which are the things American breast centres buy for density notification compliance rather than for detection.

Lunit: Is pricing published?

No. It is quoted per study or per annual volume, by product, with on premises and cloud priced differently.

Share

Related pages

More on Lunit

More on Phreesia

Keep looking

Other head to heads